COVID -19 pandemic has resulted in more than 257 million infections and 5.15 million deaths worldwide. Several drug interventions targeting multiple stages of the pathogenesis of COVID -19 can significantly reduce induced infection and thus mortality. In this study, we first develop SIV model at within-host level by incorporating the intercellular time delay and analyzing the stability of equilibrium points. The model dynamics admits a disease-free equilibrium and an infected equilibrium with their stability based on the value of the basic reproduction number R 0. We then formulate an optimal control problem with antiviral drugs and second-line drugs as control measures and study their roles in reducing the number of infected cells and viral load. The comparative study conducted in the optimal control problem suggests that if the first-line antiviral drugs show adverse effects, considering these drugs in reduced amounts along with the second-line drugs would be very effective in reducing the number of infected cells and viral load in a COVID-19 infected patient. Later, we formulate a time-optimal control problem with the goal of driving the system from any initial state to the desired infection-free equilibrium state in finite minimal time. Using Pontryagin’s Minimum Principle, it is shown that the optimal control strategy is of the bang-bang type, with the possibility of switching between two extreme values of the optimal controls. Numerically, it is shown that the desired infection-free state is achieved in a shorter time when the higher values of the optimal controls. The results of this study may be very helpful to researchers, epidemiologists, clinicians and physicians working in this field.
The COVID-19 pandemic has resulted in more than 524 million cases and 6 million deaths worldwide. Various drug interventions targeting multiple stages of COVID-19 pathogenesis can significantly reduce infection-related mortality. The current within-host mathematical modeling study addresses the optimal drug regimen and efficacy of combination therapies in the treatment of COVID-19. The drugs/interventions considered include Arbidol, Remdesivir, Interferon (INF) and Lopinavir/Ritonavir. It is concluded that these drugs, when administered singly or in combination, reduce the number of infected cells and viral load. Four scenarios dealing with the administration of a single drug, two drugs, three drugs and all four are discussed. In all these scenarios, the optimal drug regimen is proposed based on two methods. In the first method, these medical interventions are modeled as control interventions and a corresponding objective function and optimal control problem are formulated. In this framework, the optimal drug regimen is derived. Later, using the comparative effectiveness method, the optimal drug regimen is derived based on the basic reproduction number and viral load. The average number of infected cells and viral load decreased the most when all four drugs were used together. On the other hand, the average number of susceptible cells decreased the most when Arbidol was administered alone. The basic reproduction number and viral load decreased the most when all four interventions were used together, confirming the previously obtained finding of the optimal control problem. The results of this study can help physicians make decisions about the treatment of the life-threatening COVID-19 infection.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.